PharmaEngineROCO:4162 +4.43%78 FCF Yield % is 19.70 as of Jul. 03, 2026, which is 764% above its 10-year median of 2.28. GuruFocus rates ROCO:4162 with a GF Score™ of 78/100 and a GF Value™ of NT$115.11 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, PharmaEngine ranks better than 98.94% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
PharmaEngine FCF Yield % Related Terms
PharmaEngine FCF Yield % Historical Data
* Premium members only.
The historical data trend for PharmaEngine's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4162 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, PharmaEngine's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's FCF Yield % distribution charts can be found below:
* The bar in red indicates where PharmaEngine's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaEngine (ROCO:4162) has a FCF Yield % of 19.70 as of Jul. 03, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on PharmaEngine and its competitors. This is 764% above median its historical median of 2.28. According to the industry distribution chart, PharmaEngine ranks #15 out of 1413 companies in the Biotechnology industry, placing it in the top 1.1%.
Is PharmaEngine's FCF Yield % too high?
PharmaEngine's current FCF Yield % of 19.70 is 764% above median its 10-year median of 2.28. Based on the distribution chart, PharmaEngine ranks #15 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaEngine has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #15 out of 1413 companies for FCF Yield %. This places PharmaEngine in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on PharmaEngine and its competitors. PharmaEngine's current FCF Yield % is 19.70, which is 764% above median its own 10-year median of 2.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.11, compared to a current price of NT$63.70 — trading 44.7% below its estimated fair value. The current FCF Yield % is 19.70, which is 764% above median its 10-year median of 2.28. PharmaEngine's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current FCF Yield % is 19.70 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$63.70 is trading 44.7% below its estimated GF Value™ of NT$115.11.
GuruFocus considers PharmaEngine to be Significantly Undervalued.
Key valuation signals for ROCO:4162:
FCF Yield %: 19.70 (764% above median its 10-year median of 2.28)
GF Value™: NT$115.11 vs. price of NT$63.70 (44.7% below fair value)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
78GF Score
Get the complete analysis for ROCO:4162
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
